Brain metastases are a frequent and grave complication of non-small cell lung carcinoma
(NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and …

Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …

Background Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors are controversial in the treatment of patients with brain metastases from non-small …

Brain metastases (BM) is one of the most crucial distant metastases in patients with non-
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …

Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …

Background: Brain metastases are a common occurrence in patients with non-small-cell
lung cancer (NSCLC). Whole-brain radiotherapy (WBRT) is the standard therapy; more …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …

Brain metastasis from non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) mutations is a hot research topic, but also a difficulty in targeted NSCLC …

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …